Fasting glucose in acute myocardial infarction: Incremental value for long-term mortality and relationship with left ventricular systolic function

Diabetes Care

Volumn 30, Issue 4, 2007, Pages 960-966

  Aronson, Doron ^a   Hammerman, Haim ^a   Kapeliovich, Michael R ^a   Suleiman, Abeer ^a   Agmon, Yoram ^a   Beyar, Rafael ^a   Markiewicz, Walter ^a   Suleiman, Mahmoud ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOPLASTY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DIET THERAPY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART EJECTION FRACTION; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS;

ADULT; AGED; BLOOD GLUCOSE; DIABETIC ANGIOPATHIES; FASTING; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISRAEL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SYSTOLE; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 34147124512     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-1735     Document Type: Article

References (40)

1. Pinto DS, Skolnick AH, Kirtane AJ, Murphy SA, Barron HV, Giugliano RP, Cannon CP, Braunwald E, Gibson CM: U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 46:178-180, 2005
2. Straumann E, Kurz DJ, Muntwyler J, Stettler I, Furrer M, Naegeli B, Frielingsdorf J, Schuiki E, Mury R, Bertel O, Spinas GA: Admission glucose concentrations independently predict early and late mortality in patients with acute myocardial infarction treated by primary or rescue percutaneous coronary intervention. Am Heart J 150:1000-1006, 2005
3. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, Havranek EP, Krumholz HM: Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 111:3078-3086, 2005
4. Bhadriraju S, Ray KK, DeFranco AC, Barber K, Bhadriraju P, Murphy SA, Morrow DA, McCabe CH, Gibson CM, Cannon CP, Braunwald E: Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial. Am J Cardiol 97:1573-1577, 2006
5. Goyal A, Mahaffey KW, Garg J, Nicolau JC, Hochman JS, Weaver WD, Theroux P, Oliveira GB, Todaro TG, Mojcik CF, Armstrong PW, Granger CB: Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J 27:1289-1297, 2006
6. Kadri Z, Danchin N, Vaur L, Cottin Y, Gueret P, Zeller M, Lablanche JM, Blanchard D, Hanania G, Genes N, Cambou JP: Major impact of admission glycaemia on 30 day and one year mortality in nondiabetic patients admitted for myocardial infarction: results from the nationwide French USIC 2000 study. Heart 92:910-915, 2006
7. Suleiman M, Hammerman H, Boulos M, Kapeliovich MR, Suleiman A, Agmon Y, Markiewicz W, Aronson D: Fasting glucose is an important independent risk factor for 30-day mortality in patients with acute myocardial infarction: a prospective study. Circulation 111:754-760, 2005
8. Ohman EM, Granger CB, Harrington RA, Lee KL: Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA 284:876-878, 2000
9. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E: TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102:2031-2037, 2000
10. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg PG, Gore JM, Budaj A, Avezum A, Flather MD, Fox KA: A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 291:2727-2733, 2004
11. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E: The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 284:835-842, 2000
12. Witteles RM, Tang WH, Jamali AH, Chu JW, Reaven GM, Fowler MB: Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J Am Coll Cardiol 44:78-81, 2004
13. Suskin N, McKelvie RS, Burns RJ, Latini R, Pericak D, Probstfield J, Rouleau JL, Sigouin C, Solymoss CB, Tsuyuki R, White M, Yusuf S: Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 21:1368-1375, 2000
14. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, Umemura T, Nakamura S, Yoshida M: Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction. Am Heart J 146:674-678, 2003
15. O'Sullivan JJ, Conroy RM, Robinson K, Hickey N, Mulcahy R: In-hospital prognosis of patients with fasting hyperglycemia after first myocardial infarction. Diabetes Care 14:758-760, 1991
16. Thomassen AR, Mortensen PT, Nielsen TT, Falstie-Jensen N, Thygesen K, Henningsen P: Altered plasma concentrations of glutamate, alanine and citrate in the early phase of acute myocardial infarction in man. Eur Heart J 7:773-778, 1986
17. Oswald GA, Smith CC, Betteridge DJ, Yudkin JS: Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction. Br Med J (Clin Res Ed) 293:917-922, 1986
18. Bellodi G, Manicardi V, Malavasi V, Veneri L, Bernini G, Bossini P, Distefano S, Magnanini G, Muratori L, Rossi G, et al.: Hyperglycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus. Am J Cardiol 64:885-888, 1989
19. Alpert JS, Thygesen K, Antman E, Bassand JP: Myocardial infarction redefined-a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36:959-969, 2000
20. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ: Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440-1463, 2005
21. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160-3167, 2003
22. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA: Evaluating the yield of medical tests. JAMA 247:2543-2546, 1982
23. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837-845, 1988
24. Tenenbaum A, Motro M, Fisman EZ, Leor J, Freimark D, Boyko V, Mandelzweig L, Adler Y, Sherer Y, Behar S: Functional class in patients with heart failure is associated with the development of diabetes. Am J Med 114:271-275, 2003
25. Ceriello A: Acute hyperglycaemia: a 'new' risk factor during myocardial infarction. Eur Heart J 26:328-331, 2005
26. Oswald GA, Smith CC, Delamothe AP, Betteridge DJ, Yudkin JS: Raised concentrations of glucose and adrenaline and increased in vivo platelet activation after myocardial infarction. Br Heart J 59:663-671, 1988
27. Bernal-Mizrachi C, Weng S, Feng C, Finck BN, Knutsen RH, Leone TC, Coleman T, Mecham RP, Kelly DP, Semenkovich CF: Dexamethasone induction of hypertension and diabetes is PPAR-α dependent in LDL receptor-null mice. Nat Med 9:1069-1075, 2003
28. Takano A, Haruta T, Iwata M, Usui I, Uno T, Kawahara J, Ueno E, Sasaoka T, Kobayashi M: Growth hormone induces cellular insulin resistance by uncoupling phosphatidylinositol 3-kinase and its downstream signals in 3T3-L1 adipocytes. Diabetes 50:1891-1900, 2001
29. Attvall S, Eriksson BM, Fowelin J, von Schenck H, Lager I, Smith U: Early post-hypoglycemic insulin resistance in man is mainly an effect of β-adrenergic stimulation. J Clin Invest 80:437-442, 1987
30. Rouleau JL, Packer M, Moye L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F, et al.: Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 24:583-591, 1994
31. Nian M, Lee P, Khaper N, Liu P: Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94:1543-1553, 2004
32. Miles PD, Romeo OM, Higo K, Cohen A, Rafaat K, Olefsky JM: TNF-α-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes 46:1678-1683, 1997
33. Marrero MB, Fulton D, Stepp D, Stern DM: Angiotensin II-induced insulin resistance and protein tyrosine phosphatases. Arterioscler Thromb Vasc Biol 24:2009-2013, 2004
34. Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling: behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35:569-582, 2000
35. Pfeffer MA, Braunwald E: Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 81:1161-1172, 1990
36. Taegtmeyer H, McNulty P, Young ME: Adaptation and maladaptation of the heart in diabetes: part I: general concepts. Circulation 105:1727-1733, 2002
37. Depre C, Vanoverschelde JL, Taegtmeyer H: Glucose for the heart. Circulation 99:578-588, 1999
38. Das UN: Is insulin an endogenous cardioprotector? Crit Care 6:389-393, 2002
39. Jonassen AK, Brar BK, Mjos OD, Sack MN, Latchman DS, Yellon DM: Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J Mol Cell Cardiol 32:757-764, 2000
40. Johan Groeneveld AB, Beishuizen A, Visser FC: Insulin: a wonder drug in the critically ill? Crit Care 6:102-105, 2002